References
- Kelly G. Body temperature variability (Part 1): a review of the history of body temperature and its variability due to site selection, biological rhythms, fitness, and aging. Altern Med Rev. 2006;11(4):278–293.
- Stevens RJ, Oke J, Perera R. Statistical models for the control phase of clinical monitoring. Stat Methods Med Res. 2010;19(4):394–414.
- Wunderlich CA, Seguin E. Medical thermometry, and human temperature. New York: William Wood & Company; 1871.
- Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA. 1992;268(12):1578–1580.
- Sund-Levander M, Forsberg C, Wahren LK. Normal oral, rectal, tympanic and axillary body temperature in adult men and women: a systematic literature review. Scand J Caring Sci. 2002;16(2):122–128.
- Horvath SM, Menduke H, Piersol GM. Oral and rectal temperatures of man. J Am Med Assoc. 1950;144(18):1562–1565.
- NICE Clinical Guideline GC151. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. London: National Institute for Health and Care Excellence: Guidance. 2012.
- National Confidential Enquiry into Patient Outcome and Death. For better, for worse? A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy. London: Healthcare Quality Improvement Partnership; 2008.
- Clarke RT, Jenyon T, van Hamel Parsons V, et al. Neutropenic sepsis: management and complications. Clin Med (Lond). 2013;13(2):185–187.
- Clarke RT, Warnick J, Stretton K, et al. Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. Br J Haematol. 2011;153(6):773–779.
- Clarke RT, Bird S, Kakuchi I, et al. The signs, symptoms and help-seeking experiences of neutropenic sepsis patients before they reach hospital: a qualitative study. Support Care Cancer. 2015;23(9):2687–2694.
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
- Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
- Roghmann MC, Warner J, Mackowiak PA. The relationship between age and fever magnitude. Am J Med Sci. 2001;322(2):68–70.
- Ahn S, Fessler JA. Standard errors of mean, variance, and standard deviation estimators. Ann Arbor (MI): EECS Department, The University of Michigan; 2003.
- Kelly GS. Body temperature variability (Part 2): masking influences of body temperature variability and a review of body temperature variability in disease. Altern Med Rev. 2007;12(1):49–62.
- Bailleul F, Levi F, Reinberg A, et al. Interindividual differences in the circadian hematologic time structure of cancer patients. Chronobiol Int. 1986;3(1):47–54.
- Carpenter JS, Gilchrist JM, Chen K, et al. Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Menopause. 2004;11(4):375–381.
- Weycker D, Li X, Edelsberg J, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. JOP. 2015;11(1):47–54.